Although defects in other key HRR proteins such as PALB2 account for some of these HRD-positive tumours, it is also important to highlight that some HRR genes, in particular BRCA1 and RAD51C, show high levels of promoter hypermethylation leading to gene silencing in breast and ovarian cancer [17,18]. The gene discussed is RAD51C; the disease is neoplasm.